Acumen Pharmaceuticals, Inc. - 8-K Filing
Acumen Pharmaceuticals to cease development of sabirnetug after Phase 2 ALTITUDE-AD trial failed to meet primary endpoint. (Items: 7.01 Regulation FD Disclosure, 8.01 of this Current Report on Form 8-K (this “Report”), 9.01 Financial Statements and Exhibits)
Tickers: $ABOS